Publications by authors named "Shoghag Khoudigian"
There is growing interest in novel insulin management systems that improve glycemic control. This study aimed to evaluate the cost-effectiveness of smart connected insulin re-usable pens or caps for disposable insulin pens versus pens without connected capabilities in the management of adult patients with Type 1 diabetes (T1DM) from a Canadian societal perspective. The IQVIA Core Diabetes Model was utilized to conduct the analyses.
View Article and Find Full Text PDFArticle Synopsis
- Lorlatinib is the only targeted therapy in Canada for patients with ALK-positive non-small cell lung cancer (NSCLC) who have not responded to second-generation ALK TKIs, addressing a significant treatment gap.
- A study involving 59 patients showed that lorlatinib had a median treatment duration of 15.3 months, with over half of the patients still on treatment after 12 months.
- Patients also experienced improved quality of life, with a notable increase in health utility scores within the first three months, suggesting lorlatinib effectively manages both survival and quality of life for these patients.
Background: The popularity of surgery for acute displaced midshaft clavicle fractures has been fuelled by early randomized controlled trials (RCTs) showing improved rates of radiographic union and perceived functional benefits compared with nonoperative approaches. We performed a meta-analysis to determine the effect of operative and nonoperative interventions on the risk of secondary operation and complications and on long-term function.
Methods: We search MEDLINE, Embase and the Cochrane Central Register of Controlled Trials for reports of relevant RCTs published to Mar.
Background: Surrogate outcomes are a significant challenge in drug evaluation for health technology assessment (HTA) agencies. The research objectives were to: identify factors associated with surrogate use and acceptability in Canada's Common Drug Review (CDR) recommendations, and compare the CDR with other HTA or regulatory agencies regarding surrogate concerns.
Methods: Final recommendations were identified from CDR inception (September 2003) to December 31, 2010.